Medtide Inc. (3880) Receives CSRC Filing Notice for H Share Full Circulation

Bulletin Express

02/05

Medtide Inc. announced that, following the acceptance of its H Share Full Circulation application by the China Securities Regulatory Commission (CSRC) on July 27, 2025, a filing notice was issued on February 5, 2026. According to the filing notice, the conversion and listing process may proceed, and if it is not completed within 12 months from the notice’s date, an updated filing with the CSRC will be required.

Details of the conversion and listing plan have not been finalized. The H Share Full Circulation, conversion, and listing remain subject to further procedural requirements by the CSRC, The Stock Exchange of Hong Kong Limited, and other relevant domestic and overseas regulatory authorities. Shareholders and potential investors are advised to exercise caution when dealing in the company’s securities.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1141129814"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1141129814\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1141129814?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-05 20:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1141129814","market":"us","top_or_hot":-1,"title":"Medtide Inc. (3880) Receives CSRC Filing Notice for H Share Full Circulation","media":"Bulletin Express","content":"<p>Medtide Inc. announced that, following the acceptance of its H Share Full Circulation application by the China Securities Regulatory Commission (CSRC) on July 27, 2025, a filing notice was issued on February 5, 2026. According to the filing notice, the conversion and listing process may proceed, and if it is not completed within 12 months from the notice’s date, an updated filing with the CSRC will be required.</p>\n<p>Details of the conversion and listing plan have not been finalized. The H Share Full Circulation, conversion, and listing remain subject to further procedural requirements by the CSRC, The Stock Exchange of Hong Kong Limited, and other relevant domestic and overseas regulatory authorities. Shareholders and potential investors are advised to exercise caution when dealing in the company’s securities.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Medtide Inc. (3880) Receives CSRC Filing Notice for H Share Full Circulation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMedtide Inc. (3880) Receives CSRC Filing Notice for H Share Full Circulation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-02-05 20:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Medtide Inc. announced that, following the acceptance of its H Share Full Circulation application by the China Securities Regulatory Commission (CSRC) on July 27, 2025, a filing notice was issued on February 5, 2026. According to the filing notice, the conversion and listing process may proceed, and if it is not completed within 12 months from the notice’s date, an updated filing with the CSRC will be required.</p>\n<p>Details of the conversion and listing plan have not been finalized. The H Share Full Circulation, conversion, and listing remain subject to further procedural requirements by the CSRC, The Stock Exchange of Hong Kong Limited, and other relevant domestic and overseas regulatory authorities. Shareholders and potential investors are advised to exercise caution when dealing in the company’s securities.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03880","symbol_name":"泰德医药","start_time":0,"source_url":"","article_id":"1141129814","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1141129814","pubTimestamp":1770293122,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Medtide Inc. announced that, following the acceptance of its H Share Full Circulation application by the China Securities Regulatory Commission (CSRC) on July 27, 2025, a filing notice was issued on...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03880":"泰德医药"},"translate_title":"Medtide Inc.(3880)收到证监会H股全流通备案通知书","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03880":1},"content_text":"Medtide Inc. announced that, following the acceptance of its H Share Full Circulation application by the China Securities Regulatory Commission (CSRC) on July 27, 2025, a filing notice was issued on February 5, 2026. According to the filing notice, the conversion and listing process may proceed, and if it is not completed within 12 months from the notice’s date, an updated filing with the CSRC will be required.\nDetails of the conversion and listing plan have not been finalized. The H Share Full Circulation, conversion, and listing remain subject to further procedural requirements by the CSRC, The Stock Exchange of Hong Kong Limited, and other relevant domestic and overseas regulatory authorities. Shareholders and potential investors are advised to exercise caution when dealing in the company’s securities.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}